L A Kroger
Overview
Explore the profile of L A Kroger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Denardo G, Denardo S, ODonnell R, Kroger L, Kukis D, Meares C, et al.
Clin Lymphoma
. 2001 Nov;
1(2):118-26.
PMID: 11707820
Radioimmunotherapy using radiolabeled monoclonal antibodies against tumor-associated antigens has been efficacious, particularly in the treatment of radiosensitive malignancies such as lymphoma. Antilymphoma monoclonal antibody Lym-1, labeled with copper-67 ((67)Cu), iodine-131...
2.
Kroger L, Denardo G, Gumerlock P, Xiong C, Winthrop M, Shi X, et al.
Cancer Biother Radiopharm
. 2001 Jul;
16(3):213-25.
PMID: 11471486
Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. Apoptosis has been suggested to be a major mechanism for cell...
3.
ODonnell R, Denardo S, Miers L, Kukis D, Mirick G, Kroger L, et al.
Cancer Biother Radiopharm
. 2000 Jun;
13(5):351-61.
PMID: 10851425
Despite effective therapies for non-Hodgkin's lymphoma (NHL), the majority of patients are not cured. Radioimmunotherapy (RIT) has shown good results in preclinical and clinical trials even in patients that are...
4.
Denardo G, Denardo S, Lamborn K, Goldstein D, Levy N, Lewis J, et al.
Cancer Biother Radiopharm
. 2000 Jun;
13(4):239-54.
PMID: 10850360
Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated...
5.
Denardo S, Kroger L, Mackenzie M, Mirick G, Shen S, Denardo G
Cancer Biother Radiopharm
. 2000 Jun;
13(1):1-12.
PMID: 10850337
A patient with aggressive, chemotherapy-resistant non-Hodgkins lymphoma (NHL) was treated with 131I-Lym-1, a mouse antibody, on a protocol designed for serial therapy. Human anti-mouse antibody (HAMA) developed within 1 month...
6.
ODonnell R, Leigh B, Christensen S, Goldstein D, Kukis D, Shen S, et al.
Cancer Biother Radiopharm
. 2000 Jun;
14(3):167-76.
PMID: 10850301
Standard therapy for AIDS associated NHL (AANHL) is toxic and often ineffective. Radioimmunotherapy (RIT) is an appealing alternative to chemotherapy because of the radiosensitivity of NHL and the ability of...
7.
Denardo G, ODonnell R, Shen S, Kroger L, Yuan A, Meares C, et al.
J Nucl Med
. 2000 May;
41(5):952-8.
PMID: 10809213
Unlabelled: Several monoclonal antibodies, including Lym-1, have proven effective for treatment of hematologic malignancies. Lym-1, which preferentially targets malignant lymphocytes, has induced therapeutic responses and prolonged survival in patients with...
8.
Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
Denardo S, Burke P, Leigh B, ODonnell R, Miers L, Kroger L, et al.
Cancer Biother Radiopharm
. 2000 Mar;
15(1):71-9.
PMID: 10740655
Radioimmunotherapy (RIT) has been hampered by delivery of only a small fraction of the administered dose of radiolabeled MAb to tumor. A strategy for creating and controlling tumor vascular permeability...
9.
Kroger L, Denardo S, Denardo G, Xiong C, Winthrop M, Gumerlock P
Clin Cancer Res
. 1999 Nov;
5(10 Suppl):3010s-3014s.
PMID: 10541336
Radioimmunotherapy using monoclonal antibodies against tumor-associated antigens has been particularly promising in the treatment of radiosensitive malignancies such as lymphoma. 67Cu has excellent physical and biochemical properties for radioimmunotherapy. 67Cu-2IT-BAT-Lym-1...
10.
Richman C, Denardo S, ODonnell R, Goldstein D, Shen S, Kukis D, et al.
Clin Cancer Res
. 1999 Oct;
5(10 Suppl):3243s-3248s.
PMID: 10541370
Radioimmunoconjugates of 170H.82 (m170), a panadenocarcinoma monoclonal antibody, are effective for imaging primary and metastatic breast cancer. To evaluate m170 as a targeting agent for therapy, we developed (111)In- and...